Top Markets
#1 Velas Velas +480.91%
#2 Siren Siren +109.58%
#3 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#4 Venom Venom +45.46%
#5 Gigachad Gigachad +23.69%
#6 Ontology Ontology +20.18%
#7 Scor Scor +17.06%
#8 Dacxi Dacxi +16.49%
#9 Strategic Oil Supply Strategic Oil Supply +15.04%
#10 TRIA TRIA +14.71%
Coin of the day
Velas Velas
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Rangering i aksjer #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Aksjekurs
$0.0416118
Markedsverdi
$12.78M
Endring (1 dag)
1.72%
Endring (1 år)
-22.01%
Land
AU
Handel Noxopharm Limited (NOX)

Kategori

Healthcare
Antall utestående aksjer for Noxopharm Limited (NOX)
Antall utestående aksjer per December 2025: 292.24M
Ifølge Noxopharm Limited sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 292.24M. Ved slutten av June 2024 hadde selskapet 292.26M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Noxopharm Limited (NOX) fra 2016 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
2026 (TTM) 292.24M -0.08%
2025 292.47M 0.07%
2024 292.26M 0.01%
2023 292.24M 0.35%
2022 291.22M 10.37%
2021 263.85M 90.70%
2020 138.36M 0.15%
2019 138.15M 16.06%
2018 119.03M 35.93%
2017 87.57M 160.94%
2016 33.56M 0.00%
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 4.45B 1,422.00%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -13.12%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 102.90M -64.79%
US
UCB SA UCB SA
UCB SA
UCB.BR
 190.00M -34.99%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 483.58M 65.47%
AU